Skip to main content
SpringerLink
Log in

The safety of iloprost in systemic sclerosis in a real-life experience

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Iloprost (ILO) is employed intravenously for the treatment of severe Raynaud phenomenon (RP) and digital ulcers (DU) in systemic sclerosis (SSc). The aim of this study was to evaluate the safety and tolerability of the intravenous treatment with ILO in different phases of SSc. Eighty-one consecutive non-selected SSc patients, all on nifedipine, with moderate RP, treated with ILO infusion, were retrospectively evaluated. Patients were sub classified according to the edematous or fibrotic/atrophic cutaneous phase of the disease. ILO was infused with a progressive increase of the dosage up to the achievement of patient’s tolerance, 1 day/week. In cases of slower infusion regimen due to adverse events (AE) at the beginning of the administration, patients received a lower dose of the drug (not possible to quantify precisely the final cumulative dosage). 16/81 SSc patients presented digital edema, 5 developed diarrhea, and 9 developed transient hypotension during the infusion at 20 ml/h that ameliorated when the drug was withdrawn. Moreover, 10/16 edematous patients experienced significant and painful digital swelling, unlike patients in the fibrotic group (p < 0.0001); 11/16 patients reported flushing and 7/16 headache, always controlled with dose tapering below 10 ml/h. In the atrophic/fibrotic phase patients (65/81), 10 developed diarrhea and 24 hypotension at infusion rate of 20 ml/h that led to temporary withdrawal of the drug. When ILO was restarted and kept below 10 ml/h, no side effects were experienced. 23/65 patients experienced flushing and 8/65 headache, all controlled with infusion reduction below 10 ml/h. In these patients, adverse events were significantly less frequent than in the edematous group (p = 0.023 and p = 0.008, respectively). Our data suggest that calcium channel blockers should be transitorily stopped while using ILO and that a pre-treatment approach might reduce or control adverse events. In patients with digital edema, ILO infusion should be carefully employed after the evaluation of patient’s drug tolerance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Matucci-Cerinic M, Kahaleh B, Wigley FM (2013) Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65:1953–1962

    Article  CAS  PubMed  Google Scholar 

  2. Frech TM, Revelo MP, Drakos SG, Murtaugh MA, Markewitz BA, Sawitzke AD et al (2012) Vascular leak is a central feature in the pathogenesis of systemic sclerosis. J Rheumatol 39:1385–1391

    Article  PubMed  PubMed Central  Google Scholar 

  3. Matucci-Cerinic M, Manetti M, Bruni C, Chora I, Bellando Randone S, Lepri G et al (2017) The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event? Arthritis Res Ther 6(19):162

    Article  Google Scholar 

  4. Rabquer BJ, Koch AE (2012) Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 14:56–63

    Article  PubMed  Google Scholar 

  5. Ennis H, Hughes M, Anderson ME, Wilkinson J, Herrick A (2016) Calcium channel blockers for primary Raynaud’s phenomenon. Cochrane Database Syst Rev 2:CD002069

    PubMed  Google Scholar 

  6. Herrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O'Connell D, Vázquez-Abad MD, Denton CP (2011) Modified-release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 63:775–782

    Article  CAS  PubMed  Google Scholar 

  7. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841–1847

    Article  CAS  PubMed  Google Scholar 

  8. Hettema ME, Zhang D, Bootsma H, Kallenberg CGM (2007) Bosentan therapy for patients with severe Raynaud’s phenomenon in systemic sclerosis. Ann Rheum Dis 66:1398–1399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA, Morganti A, Kramer F, Korn JH, Seibold JR (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32–38

    Article  CAS  PubMed  Google Scholar 

  10. Della Rossa A, Doveri M, D’Ascanio A, Tavoni A, Consensi A, Neri R et al (2011) Oral sildenafil in skin ulcers secondary to systemic sclerosis. Scand J Rheumatol 40:323–325

    Article  CAS  PubMed  Google Scholar 

  11. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjal L et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620–628

    Article  CAS  PubMed  Google Scholar 

  12. Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, Kambayashi J, Orlandi C, Czerwiec FS (2004) Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 50:3994–4001

    Article  CAS  PubMed  Google Scholar 

  13. García de la Peña Lefebvre P, Nishishinya MB, Pereda CA, Loza E, Sifuentes Giraldo WA, Román Ivorra JA, Carreira P, Rúa-Figueroa I, Pego-Reigosa JM, Muñoz-Fernández S (2015) Efficacy of Raynaud’s phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. Rheumatol Int 35:1447–1459

    Article  PubMed  Google Scholar 

  14. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199–206

    Article  CAS  PubMed  Google Scholar 

  15. Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM et al (2002) Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J 16:1949–1951

    Article  CAS  PubMed  Google Scholar 

  16. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T et al (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001(108):241–250

    Article  Google Scholar 

  17. Lindemann S, Gierer C, Darius H (2003) Prostacyclin inhibits adhesion of polymorphonuclear leukocytes to human vascular endothelial cells due to adhesion molecule independent regulatory mechanisms. Basic Res Cardiol 98(1):8–15

    Article  CAS  PubMed  Google Scholar 

  18. Fiessinger JN, Schäfer M (1990) Trial of iloprost versus aspirin treatment for critical limb ischemia for thromboangiitis obliterans. Lancet 335:555–557

    Article  CAS  PubMed  Google Scholar 

  19. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP (1992) Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19:1407–1414

    CAS  PubMed  Google Scholar 

  20. Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, Arpaia G, Sardina M, Origgi L, Vanoli M (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503–508

    CAS  PubMed  Google Scholar 

  21. Veale DJ, Muir AH, Morley KD, Belch JJF (1995) Treatment of vasculitic leg ulcers in connective tissue disease with iloprost. Clin Rheumatol 14:187–191

    Article  CAS  PubMed  Google Scholar 

  22. Zahavi J, Charach G, Schafer R, Toeg A, Zahavi M (1993) Ischaemic necrotic toes associated with antiphospholipid syndrome and treated with iloprost. Lancet 342:862

    Article  CAS  PubMed  Google Scholar 

  23. Belch JJ, Capell HA, Cooke ED, Kirby JD, Lau CS, Madhok R, Murphy E, Steinberg M (1995) Oral iloprost as a treatment for Raynaud’s syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 54:197–200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kyle MV, Belcher G, Hazleman BL (1992) Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud’s phenomenon. J Rheumatol 19:1403–1406

    CAS  PubMed  Google Scholar 

  25. Lau CS, Belch JJ, Madhok R, Cappell H, Herrick A, Jayson M, Thompson JM (1993) A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud’s phenomenon secondary to systemic sclerosis. Clin Exp Rheumatol 11:35–40

    CAS  PubMed  Google Scholar 

  26. McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF et al (1988) Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud’s phenomenon in systemic sclerosis. Ann Rheum Dis 47:43–47

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Yardumian DA, Isenberg DA, Rustin M, Belcher G, Snaith ML, Dowd PM et al (1988) Successful treatment of Raynaud’s syndrome with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 27:220–226

    Article  CAS  PubMed  Google Scholar 

  28. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2:CD000953

    Google Scholar 

  29. Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, Kirby JD (1989) Comparison of intravenous infusion of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double blind randomised study. Br Med J 298:561–564

    Article  CAS  Google Scholar 

  30. Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, Novo S (2006) Iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology 45:999–1004

    Article  CAS  PubMed  Google Scholar 

  31. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737–2747

    Article  PubMed  PubMed Central  Google Scholar 

  32. Bettoni L, Geri A, Airò P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R (2002) Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21:244–250

    Article  CAS  PubMed  Google Scholar 

  33. Bali G, Schwantzer G, Aberer F, Kraenke B, Aberer E (2011) Discontinuing long-term iloprost treatment for Raynaud’s phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study. Acta Dermatovenerol Alp Pannonica Adriat 20:13–21

    CAS  PubMed  Google Scholar 

  34. Colaci M, Lumetti F, Giuggioli D, Guiducci S, Bellando-Randone S, Fiori G et al (2017) Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study. Clin Exp Rheumatol 106:179–183

    Google Scholar 

  35. Lepri G, Bellando-Randone S, Guiducci S, Giani I, Bruni C, Blagojevic J et al (2015) Esophageal and anorectal involvement in patients with very early diagnosis of systemic sclerosis (VEDOSS): report from a single EUSTAR centre. Ann Rheum Dis 74:124–128

    Article  PubMed  Google Scholar 

  36. Colaci M, Sebastiani M, Giuggioli D, Manfredi A, Rossi R, Modena MG, Ferri C (2008) Cardiovascular risk and prostanoids in systemic sclerosis. Clin Exp Rheumatol 26(2):333–336

    CAS  PubMed  Google Scholar 

  37. Arreghini M, Prudente P, Maglione W, Arnoldi C, Tosi S, Marchesoni A (2001) Tolerability, safety and efficacy of iloprost infusion without peristaltic pump in systemic sclerosis. Reumatismo 53:140–144

    PubMed  Google Scholar 

  38. Torley HI, Madhok R, Capell HA, Brouwer RM, Maddison PJ, Black CM, Englert H, Dormandy JA, Watson HR (1991) A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud’s phenomenon secondary to connective tissue diseases. Ann Rheum Dis 50:800–804

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Caramaschi P, Martinelli N, Volpe A, Pieropan S, Tinazzi I, Patuzzo G, Mahamid H, Bambara LM, Biasi D (2009) A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. Clin Rheumatol 28:807–813

    Article  PubMed  Google Scholar 

  40. Kawald A, Burmester GR, Huscher D, Sunderkötter C, Riemekasten G (2008) Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud’s phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol 35:1830–1837

    CAS  PubMed  Google Scholar 

  41. De Cata A, Inglese M, Molinaro F, De Cosmo S, Rubino R, Bernal M et al (2016) Digital ulcers in scleroderma patients: a retrospective observational study. Int J Immunopathol Pharmacol 29:180–187

    Article  PubMed  Google Scholar 

  42. Cutolo M, Ruaro B, Pizzorni C, Ravera F, Smith V, Zampogna G, Paolino S, Seriolo B, Cimmino M, Sulli A (2014) Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol 41:881–886

    Article  CAS  PubMed  Google Scholar 

  43. Cestelli V, Manfredi A, Sebastiani M, Praino E, Cannarile F, Giuggioli D, Ferri C (2017) Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis. Mod Rheumatol 27(1):110–114

    Article  CAS  PubMed  Google Scholar 

  44. D’Amelio P, Cristofaro MA, D’Amico L, Veneziano L, Roato L, Sassi F (2010) Iloprost modulates the immune response in systemic sclerosis. BMC Immunol 11:62–68

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence and Division of Rheumatology AOUC, Florence, Italy

    S. Bellando-Randone, C. Bruni, G. Lepri, G. Fiori, F. Bartoli, ML Conforti, S. Guiducci & M. Matucci-Cerinic

  2. Rheumatology Unit, Scleroderma Unit, University of Modena and Reggio Emilia, Modena, Italy

    D. Giuggioli, M. Colaci, A. Spinella & C. Ferri

  3. Internal Medicine Unit 3, Careggi University Hospital Florence, Florence, Italy

    A. Moggi-Pignone

Authors
  1. S. Bellando-Randone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Bruni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Lepri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Fiori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Bartoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. ML Conforti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Moggi-Pignone
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Guiducci
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. Giuggioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Colaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Spinella
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C. Ferri
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M. Matucci-Cerinic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Bellando-Randone.

Ethics declarations

The retrospective study was approved by the Ethical Committee (protocol n. 282/15). All patients gave their written consent.

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bellando-Randone, S., Bruni, C., Lepri, G. et al. The safety of iloprost in systemic sclerosis in a real-life experience. Clin Rheumatol 37, 1249–1255 (2018). https://doi.org/10.1007/s10067-018-4043-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4043-0

Keywords

Search

Navigation